News Ticker

WIRE: GrowBLOX buys Nevada rights to Kyle Kushman’s cannabis strains and genetics

LAS VEGAS — GrowBLOX Sciences, Inc. (OTCQB: GBLX) announces the execution of an agreement with Kyle Kushman, Kushman Brands and Genetics LLC, and its affiliate Karma Consulting (collectively, “Kushman”).

GrowBlox

Pursuant to the agreement, GrowBLOX and its subsidiary GB Sciences Nevada, LLC (dba “Cultivation Labs”) will have exclusive rights in Nevada to Kushman’s cannabis brands, strains and genetics. Kushman also will advise GB Sciences’ Cultivation Labs on the expansion of its cannabis cultivation facility in Las Vegas, as well as operating processes and procedures based on Kushman’s methods and unique Veganic growing techniques.

Kyle Kushman (http://kylekushman.com/) is one of the most well-known and award winning cannabis cultivators in the world.  He has won 13 Cannabis Cup High Times awards, the “Oscar” of the Cannabis industry.  Kyle brings all of his diverse and award-winning strains to GB Sciences’ Cultivation Labs, including Strawberry Cough, Cherry Cough, Adonai OG, Silverback Grape Ape, Starberry, KK Stardawg and Jurassic Haze strains.  Kyle’s Veganic method of growing has been described as the next step in “organic” cultivation and has been shown to produce some of the cleanest and most efficacious cannabis in the marketplace.

GrowBLOX Founder and Chief Innovation Officer, Craig Ellins said, “The cannabis world knows about the amazing marijuana products created by Kyle Kushman, particularly his ‘Vegamatrix’ line of vegan and organic nutrients – the only nutrients capable of nurturing the cleanest and purest cannabis possible.  When one combines Kushman’s 30 years of experience and expertise and demonstrably superior nutrients with our innovative tissue culturing technology, the result can only be the best and most consistent pesticide free, natural medical marijuana products ever produced from the cannabis plant.”

(Kyle Kushman)

(Kyle Kushman)

GrowBLOX CEO, John Poss said, “This is a major win for medical marijuana patients in Nevada and a homerun for our shareholders. The exclusive on his brands together with his cultivation design expertise and his Vegamatrix nutrients will clearly give us a competitive advantage in Nevada. The eight strains he brings will complement perfectly the over 20 strains that GB Sciences has developed to offer a wide variety of treatment options to marijuana patients. This deal positions us perfectly in the medical cannabis market, but also gives us a strong position in the soon to come recreational market, which is expected to be created by a proposition vote in November of this year.”

Kushman said, “I feel that my expertise paired with the labs and systems put in place by GrowBLOX is a dream come true. Using artisanal techniques to take medical cannabis to its highest level, we are going to produce the highest quality Veganic cannabis for Nevada medical marijuana patients.”

GrowBLOX Chief Science Officer, Dr. Andrea Small-Howard, said, “The Kushman brands and genetics are among the best-known in the world among both personal and commercial growers of the cannabis plant. Growing Kushman strains in our Cultivation Labs facility in Las Vegas and using their proven cultivation methods should ensure the superior productivity, high potency and clean test results afforded by the organic nutrients in the Vegamatrix line.”

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc. (GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology and cannabis industry processes, with a “big” data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOX ™ suite of cultivation and growing chambers. To learn more about GrowBLOX Sciences, Inc., go to: http://growblox.com

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

GrowBLOX is a registered trademark of GrowBLOX Sciences, Inc.

Contact Information
Corporate:
GrowBLOX Sciences, Inc.,
3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Liz Bianco Publicity Director, liz@gbsciences.com, http://growblox.com
Investors: John Poss, j.poss@gbsciences.com

SOURCE GrowBLOX Sciences, Inc.

Related Links

http://kylekushman.com
http://growblox.com

Leave a comment